Superluminal Medicines, a Boston biotechnology company applying AI and machine learning to drug discovery, announced on September 3, 2026 the closing of an oversubscribed $60 million Series B financing. BVF Partners, L.P. led the round, which the company said will advance its lead program for rare genetic forms of obesity toward a first clinical trial. The company announced the financing through its official news release. According to the announcement, proceeds will support the initiation of a…
This article has been indexed from Unite.AI
Read the original article: